Debuting in Asus’ exciting 16-inch Zenbook A16, Qualcomm's 2026 flagship processor looks like a benchmark bombshell ready to ...
"The financing agreement provides TransCode with financial flexibility and ensures that TransCode can maintain operational momentum as we conduct our Phase 2a trial for our lead clinical program, ...
InvestorsHub on MSN
TransCode Therapeutics signs financing deal worth up to $20 million
TransCode Therapeutics Inc. (NASDAQ:RNAZ) said it has secured a financing agreement with an institutional healthcare investor that could provide the company with up to $20 million in funding. The ...
TransCode Therapeutics Inc. stock grades by Barron's. View RNAZ fundamental and sentiment analysis powered by MarketGrader.
03/03 TransCode Therapeutics, Inc. et Unleash Immuno Oncolytics, Inc. concluent un accord de licence exclusif mondial, intégralement réglé et sans redevance CI 03/03 TransCode Therapeutics Inc conclut ...
BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced today it has entered into an exclusive, worldwide, royalty-free license agreement with Unleash Immuno Oncolytics, Inc. to develop three ...
The data describe a template-driven RIG-I agonist strategy to selectively activate retinoic acid-inducible gene I (RIG-I) signaling inside tumor cells by leveraging overexpressed oncogenic microRNAs, ...
TransCode Therapeutics ( (RNAZ)) has provided an update. On February 5, 2026, TransCode Therapeutics, in collaboration with Quantum Leap Healthcare Collaborative, announced that it had submitted an ...
Add Yahoo as a preferred source to see more of our stories on Google. The trial aims to assess biological and clinical activity of TTX-MC138 in patients with MRD. Credit: Pickadook / Shutterstock.com.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results